logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10968213 B1

PDFFull Text
Date of Patent:
Apr. 06, 2021

Filed:

Jun. 27, 2019

Cyclopropanamine compound and use thereof

Applicant:

Takeda Pharmaceutical Company Limited, Osaka, JP;

Inventors:

Shigemitsu Matsumoto, Kanagawa, JP;

Yasushi Hattori, Kanagawa, JP;

Masashi Toyofuku, Kanagawa, JP;

Shinji Morimoto, Kanagawa, JP;

Masaki Daini, Kanagawa, JP;

Takuto Kojima, Kanagawa, JP;

Tomohiro Kaku, Kanagawa, JP;

Mitsuhiro Ito, Kanagawa, JP;

Assignee:

Takeda Pharmaceutical Company Limited, Osaka, JP;

Attorney:

Hamre, Schumann, Mueller & Larson, P.C.

Primary Examiner:

John M Mauro

Int. Cl.
CPC ...
C07D 417/14 (2006.01); C07D 417/12 (2006.01); C07D 409/12 (2006.01); C07D 307/79 (2006.01); C07D 407/12 (2006.01); C07D 213/82 (2006.01); C07D 333/38 (2006.01); C07D 413/14 (2006.01); C07D 231/14 (2006.01); C07D 333/40 (2006.01); C07D 285/08 (2006.01); C07D 285/135 (2006.01); C07D 231/12 (2006.01); C07D 277/56 (2006.01); C07D 409/14 (2006.01); C07D 413/12 (2006.01); C07D 307/81 (2006.01); A61P 43/00 (2006.01); A61P 35/00 (2006.01); A61P 25/28 (2006.01); A61P 25/18 (2006.01); A61P 25/16 (2006.01); A61P 25/14 (2006.01); A61P 25/08 (2006.01); A61P 25/00 (2006.01); A61K 31/343 (2006.01); A61K 31/421 (2006.01); A61K 31/433 (2006.01);
U.S. Cl.
CPC ...
C07D 417/14 (2013.01); C07D 213/82 (2013.01); C07D 231/12 (2013.01); C07D 231/14 (2013.01); C07D 277/56 (2013.01); C07D 285/08 (2013.01); C07D 285/135 (2013.01); C07D 307/79 (2013.01); C07D 307/81 (2013.01); C07D 333/38 (2013.01); C07D 333/40 (2013.01); C07D 407/12 (2013.01); C07D 409/12 (2013.01); C07D 409/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01);
Abstract

The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Find Patent Forward Citations

Loading…